Related Experiment Video
Updated: Aug 9, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives
1Department of Pharmacology, University of Bern, Bern, Switzerland. uwe.zangemeister@pki.unibe.ch
Abstract:
The efficacy of traditional anti-cancer agents comes with the price of toxicity to normal cells, which limits the success of therapy. In the past 2 decades, greater understanding of the molecular differences between malignant and normal cells has led to the development of therapies that more specifically target human tumors. These include new anti-cancer agents directed against intracellular targets associated with malignant alterations, such as increased proliferation, impaired apoptosis or angiogenesis. In addition, antibodies have been developed that are directed towards tumor-associated antigens and provide tailor-made effector functions by inhibiting cell growth, inducing apoptosis or constituting cytotoxic drug delivery systems. Since the targeted approach of anti-cancer therapies increases the exposure of malignant cells and at the same time reduces the exposure of normal tissues, it offers the promise of enhanced efficacy and lower side effects. Antibodies, immunoconjugates and liposomal drug delivery systems derived thereof are now mainstream cancer therapeutics, and by the end of 2003 17 marketed antibody-based products generated several billion in combined annual sales. This study highlights the most recent breakthroughs in antibody technology and summarizes major achievements in antibody-based cancer therapy in oncology trials.
Insights
Targeted cancer therapies, particularly antibody-based treatments, offer improved efficacy and reduced side effects compared to traditional agents. This study reviews recent advancements in antibody technology and their impact on oncology trials.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Traditional chemotherapy exhibits toxicity to normal cells, limiting therapeutic success.
- Advances in understanding molecular differences between cancer and normal cells enable targeted therapies.
- Targeted therapies aim at specific molecular alterations in malignant cells, such as proliferation, apoptosis, and angiogenesis.
Purpose of the Study:
- To highlight recent breakthroughs in antibody technology for cancer treatment.
- To summarize key achievements in antibody-based cancer therapy clinical trials.
Main Methods:
- Review of recent advancements in antibody technology.
- Analysis of clinical trial data for antibody-based cancer therapies.
- Focus on targeted agents against intracellular alterations and tumor-associated antigens.
Main Results:
- Antibody-based therapies demonstrate enhanced efficacy and reduced side effects by targeting malignant cells specifically.
- Marketed antibody products generated billions in sales by 2003, indicating widespread adoption.
- Antibodies function by inhibiting cell growth, inducing apoptosis, or serving as drug delivery systems.
Conclusions:
- Targeted antibody therapies represent a significant advancement in cancer treatment.
- The development of novel antibody technologies continues to improve cancer therapeutic strategies.
- Antibody-based treatments are now mainstream in oncology, with ongoing clinical trials demonstrating their value.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...